X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, AstraZeneca will focus on the GC012F, clinical-stage FasTCAR-enabled BCMA, and CD19 dual-targeting autologous chimeric antigen receptor T-cell therapy, a potential new treatment for relapsed or refractory multiple myeloma.
Lead Product(s): GC012F
Therapeutic Area: Oncology Product Name: GC012F
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $1,200.0 million Upfront Cash: $1,000.0 million
Deal Type: Acquisition February 22, 2024
Details:
GC012F is an autologous CAR-T therapeutic candidate dual-targeting B cell maturation antigen (BCMA) and CD19. It is being evaluated in phase 1/2 clinical trials for the treatment of relapsed/ refractory multiple myeloma.
Lead Product(s): GC012F
Therapeutic Area: Oncology Product Name: GC012F
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2024
Details:
The acquisition will enrich Astra’s growing pipeline of cell therapies with GC012F, a novel, FasTCAR-enabled BCMA and CD19 dual-targeting autologous CAR-T therapy, for multiple myeloma, haematologic malignancies and autoimmune diseases including systemic lupus erythematosus.
Lead Product(s): GC012F
Therapeutic Area: Oncology Product Name: GC012F
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $1,200.0 million Upfront Cash: $1,000.0 million
Deal Type: Acquisition December 26, 2023
Details:
Gracell lead candidate BCMA/CD19 dual-targeting inhibitor FasTCAR-T GC012F is currently being evaluated in Phase I clinical trial studies for the treatment of refractory Systemic Lupus Erythematosus.
Lead Product(s): GC012F
Therapeutic Area: Immunology Product Name: GC012F
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Details:
GC012F is a FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T product candidate, currently being evaluated for treatment of refractory systemic lupus erythematosus (rSLE).
Lead Product(s): GC012F
Therapeutic Area: Immunology Product Name: GC012F
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
GC012F is a FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T product candidate, currently being evaluated for treatment of relapsed or refractory multiple myeloma.
Lead Product(s): GC012F
Therapeutic Area: Oncology Product Name: GC012F
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
Gracell intends to use the net proceeds to fund research and development of its clinical-stage product candidates including, BCMA/CD19 dual-targeting FasTCAR-T GC012F is currently being evaluated in the clinical studies for the treatment of multiple myeloma, B-NHL and SLE.
Lead Product(s): GC012F
Therapeutic Area: Oncology Product Name: GC012F
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Vivo Capital
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 07, 2023
Details:
GC012F is a FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T product candidate, currently being evaluated for treatment of refractory systemic lupus erythematosus (SLE).
Lead Product(s): GC012F
Therapeutic Area: Immunology Product Name: GC012F
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2023
Details:
GC012F is a FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T product candidate, currently being evaluated for multiple myeloma and B-cell non-Hodgkin's lymphoma.
Lead Product(s): GC012F
Therapeutic Area: Oncology Product Name: GC012F
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2023
Details:
GC012F is an autologous CAR-T therapeutic candidate dual-targeting B cell maturation antigen (BCMA) and CD19 and is developed using Gracell's proprietary FasTCAR next-day manufacturing platform.
Lead Product(s): GC012F
Therapeutic Area: Oncology Product Name: GC012F
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
